SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DMB who wrote (1514)3/11/1998 2:45:00 AM
From: Maurice Winn  Read Replies (1) of 1762
 
DMB, thanks. Regarding the mechanism by which lymphoma cells die from Rituxan, yes, that was what Dr Saven suggested too. Maybe simple mechanical damage due to molecular banging around eh? Well, I was a civil engineer originally and physical effects seem so much simpler than all this electron flow, bonding and chemistry.

I get the impression that the Malaghan Institute is doing something a little different. I guess results will be the thing to watch, not the claims.

Regards,
Maurice
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News